Canadian Pharmacists Journal最新文献

{"title":"Three perspectives on relational professional identity formation","authors":"L. D. Jackson","doi":"10.1177/17151635221075991","DOIUrl":"https://doi.org/10.1177/17151635221075991","url":null,"abstract":"Professional identity formation is an important topic in the higher education and pharmacy literature and a key outcome of the PharmD program. Recently, Neubert et al. explored the impact of the pharmacy curriculum on professional identity formation in a cohort of students by evaluating their responses to a survey administered at 3 time points over a 2-year period (beginning of first, second and third years). Students were asked to describe what they would say to the physician when intervening on behalf of the patient to change a medication because of an allergy. Responses were analysed for the presence of indicators of patient centredness (e.g., demonstrating concern for impact on the patient) and physician collaboration (e.g., having a sense of shared care for a patient) and absence of indicators of physician deference (e.g., demonstrated by the ability to make a clear recommendation)—key aspects of relational professional identity for the pharmacist. Overall, students’ responses failed to meet expectations, often lacking a strong recommendation to the physician to prescribe an alternate drug. Study results suggest that the relational professional identity of students at 3 time points in the PharmD program was poorly developed regarding both patients and physicians. The reasons why students failed to demonstrate a skill they have been taught is open to speculation. I offer 3 perspectives that may inform curriculum delivery and hopefully enhance professional identity formation—issues related to mental models, collaboration and influencing others, and critical thinking and communication skills. The first perspective derives from the field of implementation science, which is concerned with the implementation of evidence-based interventions. The concept of mental models has been proposed as one way to view implementation challenges and guide the selection of strategies to deliver evidencebased interventions. The failure of students to deliver the anticipated intervention in such a real-world challenge could be considered a failure of implementation, possibly due to an existing mental model that fosters a perception of lower status relative to physicians. Such a perception could sabotage the training received related to patient advocacy and in interprofessional collaboration. The second perspective pertains to the concepts of collaboration and influencing others. Status, certainty, autonomy, relatedness and fairness (SCARF) have been described as 5 key areas that influence human behaviour. The SCARF model is based on the premise that the brain seeks to minimize threats and maximize rewards. Accordingly, maximizing rewards should help a person perform better, whereas being in the state of minimizing danger could lead to disengagement. The perception of threats in any of the 5 domains could sabotage the curriculum, while the perception of rewards could strengthen curricular messages and increase students’ confidence. The third perspective pertains to ","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"155 1","pages":"76 - 77"},"PeriodicalIF":1.5,"publicationDate":"2022-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48218398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CPhA launches Pharmacy Workforce Wellness initiative","authors":"Danielle Paes","doi":"10.1177/17151635221080498","DOIUrl":"https://doi.org/10.1177/17151635221080498","url":null,"abstract":"","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"155 1","pages":"85 - 85"},"PeriodicalIF":1.5,"publicationDate":"2022-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43008649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CPhA Welcomes new Chief Pharmacist Officer, Dr. Danielle Paes.","authors":"","doi":"10.1177/17151635211067098","DOIUrl":"https://doi.org/10.1177/17151635211067098","url":null,"abstract":"","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"155 1","pages":"6"},"PeriodicalIF":1.5,"publicationDate":"2021-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756368/pdf/10.1177_17151635211067098.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39825625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overcoming stigma in pharmacy practice.","authors":"Stephanie Gysel, Ross T Tsuyuki","doi":"10.1177/17151635211063188","DOIUrl":"https://doi.org/10.1177/17151635211063188","url":null,"abstract":"","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"155 1","pages":"4-5"},"PeriodicalIF":1.5,"publicationDate":"2021-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756366/pdf/10.1177_17151635211063188.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39825624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequently asked questions about naloxone: Part 3.","authors":"Ashley Cid, Alec Patten, Kelly Grindrod, Michael A Beazely","doi":"10.1177/17151635211056571","DOIUrl":"https://doi.org/10.1177/17151635211056571","url":null,"abstract":"Does naloxone break down if it is not stored properly? Naloxone should be kept between 15 to 30°C and away from direct light, but studies have shown that it is stable even when not stored in perfect conditions, such as when individuals carry naloxone with them or have a kit in a vehicle. Naloxone has been shown to be stable when frozen and thawed between the temperatures of −20 to 4°C or at high temperatures of 80°C. Although naloxone dosage forms normally carry an expiry date of 2 years, a recent study showed that naloxone for injection that had been expired for 30 years still contained more than 90% of active naloxone with limited degradation. Pharmacists should routinely offer replacement kits to patients as their kits expire. However, tell your patients that in an emergency situation, an expired or improperly stored naloxone kit can still be effective and is unlikely to cause harm.","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"155 1","pages":"9-11"},"PeriodicalIF":1.5,"publicationDate":"2021-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756371/pdf/10.1177_17151635211056571.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39825627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacists practising in family medicine groups: An evaluation 2 years after experiencing a virtual community of practice.","authors":"Line Guénette,&nbsp;Anne Maheu,&nbsp;Marie-Claude Vanier,&nbsp;Nicolas Dugré,&nbsp;Léonie Rouleau,&nbsp;Jacynthe Roy-Petit,&nbsp;Lyne Lalonde","doi":"10.1177/17151635211049235","DOIUrl":"https://doi.org/10.1177/17151635211049235","url":null,"abstract":"<p><strong>Background: </strong>In 2018, a virtual community of practice (CoP) for pharmacists working in family medicine groups (FMGs) in Quebec province was developed. The aim of this CoP-called <i>Réseau Québécois des Pharmaciens GMF</i> (RQP GMF)-was to foster best practices by supporting FMG pharmacists. This study assesses the processes and outcomes of this CoP 2 years after its creation.</p><p><strong>Methods: </strong>We performed a cross-sectional web-based study from March to May 2020. All FMG pharmacists who were registered as members of the RQP GMF (<i>n</i> = 326) were sent an invitation via a newsletter. The link to the questionnaire was also publicized in the CoP Facebook group. The questionnaire comprised a 38-item validated instrument assessing 8 dimensions of the CoP. A descriptive analysis was performed.</p><p><strong>Results: </strong>A total of 112 FMG pharmacists (34.4%) completed the questionnaire. Respondents agreed that the RQP GMF was a joint enterprise (mean score, 4.18/5), that members shared their knowledge (mean score, 3.94/5) and engaged mutually (mean score, 3.50/5) and that the RQP GMF provided support (mean score, 3.92/5) and capacity building (mean score, 4.01/5). In general, they were satisfied with the implementation process (mean score, 3.68/5) and with activities proposed (mean score, 3.79/5). A lower proportion of respondents agreed that their participation in the RQP GMF generated external impacts, which led to a smaller mean score (3.37/5) for this dimension.</p><p><strong>Conclusion: </strong>The RQP GMF, one of the first communities of practice for pharmacists practising in family medicine groups, attained most of the objectives initially intended by the CoP. These results will facilitate the adaptation of processes and activities to better fulfil members' needs. <i>Can Pharm J (Ott)</i> 2021;154:xx-xx.</p>","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"155 1","pages":"39-49"},"PeriodicalIF":1.5,"publicationDate":"2021-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39915497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practice guideline for pharmacists: The management of late-onset hypogonadism.","authors":"Aakriti Matai,&nbsp;Mariam Abdullahi,&nbsp;Nathan P Beahm,&nbsp;Cheryl A Sadowski","doi":"10.1177/17151635211047468","DOIUrl":"https://doi.org/10.1177/17151635211047468","url":null,"abstract":"Introduction Late-onset hypogonadism (LOH), also known as testosterone deficiency (TD) syndrome, is a medical condition that affects middle-aged and older men due to a decline in testosterone levels as they age. The European Male Aging Study reported a 0.4% annual decline in total testosterone and a 1.3% annual decline in free testosterone in its cohort of men aged 40 to 79 years. LOH is characterized by the presence of indicative signs and symptoms and a decrease in serum testosterone levels either due to testicular defects or defects of the hypothalamicpituitary-gonadal (HPG) axis. A large, long-term study conducted in the United Kingdom and the United States showed that up to 40% of men were obtaining testosterone without documented TD. Other studies have shown that there is a high prevalence of underdiagnosis of TD. Because of these discrepancies, it is important that practitioners be prudent in their diagnosis and management of LOH.","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"155 1","pages":"26-38"},"PeriodicalIF":1.5,"publicationDate":"2021-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b6/de/10.1177_17151635211047468.PMC8756369.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39915496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cross-Canada updates.","authors":"","doi":"10.1177/17151635211052285","DOIUrl":"https://doi.org/10.1177/17151635211052285","url":null,"abstract":"","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"154 6","pages":"374-375"},"PeriodicalIF":1.5,"publicationDate":"2021-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581811/pdf/10.1177_17151635211052285.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39624186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacy, we have an image problem . . . (and here's a solution).","authors":"Ross T Tsuyuki,&nbsp;Yazid N Al Hamarneh,&nbsp;Jonathan C H Chan,&nbsp;Jim Dobie,&nbsp;Talia M Santarossa,&nbsp;Randy So,&nbsp;Queeny Wu,&nbsp;Kaitlyn E Watson","doi":"10.1177/17151635211050029","DOIUrl":"https://doi.org/10.1177/17151635211050029","url":null,"abstract":"","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"154 6","pages":"353-354"},"PeriodicalIF":1.5,"publicationDate":"2021-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581803/pdf/10.1177_17151635211050029.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39624183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes within an anticoagulation clinic during COVID-19.","authors":"Sydney Selland,&nbsp;Norelle Evanger,&nbsp;Tammy J Bungard","doi":"10.1177/17151635211047528","DOIUrl":"https://doi.org/10.1177/17151635211047528","url":null,"abstract":"","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"154 6","pages":"381-384"},"PeriodicalIF":1.5,"publicationDate":"2021-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581812/pdf/10.1177_17151635211047528.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39712249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}